300255 Hebei Changshan Biochemical Pharmaceutical
- 11.49
- -0.37-3.12%
Hebei Changshan Biochemical Pharmaceutical News
The diet medicine sector bucked the trend. Tuoxin Pharmaceutical rose more than 12%, Haofan Biotech rose more than 5%, and Borui Pharmaceutical, Changshan Pharmaceutical, and Dezhan Health followed suit slightly.
The diet medicine sector bucked the trend. Tuoxin Pharmaceutical rose more than 12%, Haofan Biotech rose more than 5%, and Borui Pharmaceutical, Changshan Pharmaceutical, and Dezhan Health followed suit slightly.
Changshan Pharmaceutical lost 1.2 billion dollars a year by frying “diet pills”
The revenue of heparin formulation products, which is the core of Changshan Pharmaceutical, has declined sharply.
Changshan Pharmaceutical (300255.SZ) announced its 2023 annual results, turning profit into loss to $1.24 billion
Changshan Pharmaceutical (300255.SZ) released its 2023 annual report. The company's revenue was 1.41 billion yuan...
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
Dragon Tiger List丨Changshan Pharmaceutical's 20cm rise and closed the list with a net purchase of 107 million yuan
Gelonghui, April 25 | Changshan Pharmaceutical (300255.SZ) rose or stopped 20cm today, with a turnover of 530 million yuan and a turnover rate of 4.94%. According to data from the Dragon Tiger List, the “leisure group” sold five seats, with a net sale of 1987.75 million yuan. The listed seats bought 139 million yuan throughout the day and sold 32.2642 million yuan, for a total net purchase of 107 million yuan.
Effenatide was accepted, and Changshan Pharmaceutical welcomed another “20cm” increase and stop. Company: It's not about diet pills!
The same “recipe”
The concept of diet pills strengthened in early trading, and Changshan Pharmaceutical rose and stopped
The concept of diet pills strengthened in early trading, Changshan Pharmaceutical went up and down, while Boji Pharmaceutical, Hanyu Pharmaceutical, Baihua Pharmaceutical, Watson Pharmaceuticals, and Borui Pharmaceuticals followed suit.
Express News | Changshan Pharmaceutical: Application for marketing license for ebennatide injection accepted
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutica
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutical, Shuyu Pingmin, Changshan Pharmaceutical, and Dian Diagnosis fell more than 3%.
The A-share diet pills sector pulls back in the intraday period
Glonghui March 20 | Aimeike fell 3%, followed by Changshan Pharmaceutical, Hanyu Pharmaceutical, Haoyuan Pharmaceutical, Haofan Biotech, and Baihua Pharmaceutical.
Changshan Pharmaceutical (300255.SZ): SDIC Hi-Tech's shareholding ratio fell below 5%
On March 19, Gelonghui | Changshan Pharmaceutical (300255.SZ) announced that the company recently received a “Notice of Shareholding Reduction” and a “Simplified Equity Change Report” issued by SDIC Hi-Tech, a shareholder of more than 5%. SDIC Hi-Tech recently reduced its stock holdings by 38,874,100 shares through bulk trading on the Shenzhen Stock Exchange, accounting for 4.229763% of the company's total share capital. Since the previous disclosure of the “Simplified Equity Change Report”, the number of shares held by SDIC Hi-Tech has changed from 84,827,120 shares to 45,953,020 shares, accounting for a ratio of 9 to the company's total share capital
A-share changes丨Diet drug concept stocks rose, and Zhongsheng Pharmaceutical rose and stopped
Gelonghui, Feb. 27 | The A-share diet pill concept changed in the afternoon. Zhongsheng Pharmaceutical went up and down, while Nuotai Biotech, Borui Pharmaceuticals, Changshan Pharmaceutical, Shengnuo Biotech, Kanghui Pharmaceuticals, and Uningwei followed suit. According to the news, according to the drug clinical trial registration and information disclosure platform of the State Drug Administration, on February 21, the multinational pharmaceutical company Amjin announced a phase 1 study on the diet drug AMG 133. Unlike semeglutide and tirpotide, which are weekly formulations, AMG 133 is administered every 4 weeks, that is, once a month, subcutaneously, which means better adherence for patients.
Changshan Pharmaceutical (300255.SZ): Actual controller Gao Shuhua plans to transfer 5.77% of the shares to natural person Yang Minghuan by agreement
Gelonghui, Feb. 23, 丨 Changshan Pharmaceutical (300255.SZ) announced that on February 23, 2024, the company received a notice from Mr. Gao Shuhua, the controlling shareholder and actual controller, that it had signed the “Share Transfer Agreement between Gao Shuhua and Yang Minghuan on Hebei Changshan Biochemical Pharmaceutical Co., Ltd.” on February 22, 2024. Mr. Gao Shuhua plans to transfer his 53,000,000 unrestricted tradable shares of the company (accounting for 5.77% of the company's total share capital) to natural person Mr. Yang Minghuan.
Express News | Changshan Pharmaceutical: Enoxaparin sodium injection obtained the Pakistan Drug Registration Certificate
A-share diet drug concept stocks fluctuated, and Changshan Pharmaceutical rose more than 7%
Gelonghui, Feb. 22 | Changshan Pharmaceutical rose more than 7%, followed by Baihua Pharmaceutical, Hanyu Pharmaceutical, Watson Pharmaceuticals, Jinkai Biotech, and Boji Pharmaceuticals.
A-share pharmaceutical stocks rebounded across the board
Gelonghui, Feb. 20 | Weight loss pills led the way. Jinkai Biotech and Changshan Pharmaceutical rose and stopped by 20cm, multiple stocks such as Watson Pharmaceuticals, Panlong Pharmaceutical, and Longjin Pharmaceutical closed, and Hanyu Pharmaceutical and Borui Pharmaceuticals rose more than 10%.
The A-share diet drug concept continues to rise, Changshan Pharmaceutical surged more than 15%
Glonghui, Feb. 19 | Changshan Pharmaceutical surged more than 15%, Hanyu Pharmaceutical and Shengnuo Biotech rose more than 10%, and Jinkai Biotech, Borui Pharmaceuticals, Nootai Biotech, and Haofan Biotech surged ahead. According to the news, due to the influence of the movie “Hot and Hot,” sales of diet pills on platforms such as Taobao, JD, and Douyin showed an upward trend during the Spring Festival. Furthermore, the latest report by Morgan Stanley predicts that Eli Lilly, one of the “twin weight loss drugs,” is expected to become the first biopharmaceutical company with a market value of 1 trillion US dollars with Orforglipron, an oral GLP-1 drug currently being tested.
A-share diet drug concept stocks rallied
Gelonghui, Feb. 19 | Changshan Pharmaceutical rose more than 10%, Hanyu Pharmaceutical rose more than 8%, and Jinkai Biotech, Borui Pharmaceuticals, and Haofan Biotech rose more than 6%. According to the Southwest Securities Research Report, there are still thematic investment opportunities for diet pills and AI medicine this year.
“Jia Ling Lose Weight” has been trending for 4 days in a row. Will the number one investment theme in the Year of the Dragon be a comeback of the diet pill concept?
Under the popularity of the topic, the market speculates: will diet pills become the first investment theme in the Year of the Dragon?
Weight loss medicine sector boosted, Kaishengke rose more than 10%
Gelonghui, Feb. 1 | Jinkai Biotech rose more than 10%, followed by Hongbo Pharmaceutical, Haofan Biotech, and Changshan Pharmaceutical. According to the news, under the impetus of GLP-1 drugs such as simeglutide, Novo Nordisk's performance grew strongly. Revenue for the full year of 2023 was 232,261 billion Danish kroner, up 31% year on year, up 36% at constant exchange rates; operating profit increased 37% to DKK 102,574 billion, or 44% at a constant exchange rate.
Analysis
Price Target
No Data
